Skip to main navigation
  • Back to SpringWorksTx.com
  • Investors & Media
  • Contact Us
  • Linkedin
  • Twitter
SpringWorks
  • Overview
  • News & Events
    • Press Releases
    • Events & Presentations
  • Corporate Governance
  • Financial Information
    • SEC Filings
    • Annual Reports
  • Stock Information
    • Stock Quote & Chart
    • Analyst Coverage
  • Investor Resources
    • Investor FAQs
    • Investor Contacts
    • Email Alerts
  • Investors + Media
  • Medical Professionals
  • Contact Us
  • Linkedin
  • Twitter

Investor Relations

The full potential of targeted oncology is waiting to be unlocked.

Corporate Profile

SpringWorks Therapeutics is a clinical-stage biopharmaceutical company applying a precision medicine approach to acquiring, developing, and commercializing life-changing medicines to help patients suffering from devastating cancers live longer, better lives.
View Corporate Presentation

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Press Releases

11 Sep 2023
SpringWorks Therapeutics Appoints Dr. Tai-An Lin as Chief Scientific Officer
02 Aug 2023
SpringWorks Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights
07 Jun 2023
SpringWorks Therapeutics to Participate in the Goldman Sachs 44th Annual Global Healthcare Conference
05 Jun 2023
SpringWorks Therapeutics Announces PDUFA Date Extension for Nirogacestat NDA
View All

Upcoming Events

There are no upcoming events scheduled at this time.
View All Events

Featured Reports & Presentations

2022 Annual Report 14.6 MB
41st Annual J.P. Morgan Healthcare Conference Presentation 7.4 MB

Featured Pages

Blue background
Corporate Governance
Corporate Governance
Teal Background
Financial Information
Financial Information
Blue background
Stock Information
Stock Information
Teal Background
Investor Resources
Investor Resources

Springworks - Toolkits

  • Print Page
  • Email Alerts
  • RSS Feeds
  • Investor Contacts

Springworks Logo

Social Links

  • linkedin
  • twitter
Footer 1
  • Who We Are
    • Leadership & Board
    • Mission & Values
    • DE&I
    • Partners & Collaborators
  • Focus Areas
    • Rare Oncology
    • BCMA Combinations in Multiple Myeloma
    • Biomarker-Defined Metastatic Solid Tumors
Footer 2
  • Pipeline
    • Nirogacestat
    • Mirdametinib
    • Clinical Trials
    • Investigator-Initiated Research
    • Key Scientific Presentations and Publications
  • Careers
    • View Opportunities
Footer 3
  • Patients
    • Desmoid Tumors
    • NF1-PN
    • Expanded Access
  • Contact
Footer 4
  • Investors & Media
    • Press Releases
    • Events & Presentations
    • Corporate Governance
    • Financial Information
    • Stock Information
    • Investor Resources

© 2023 SpringWorks Therapeutics. All rights reserved.

Copyright Links

  • Privacy Policy
  • Terms of Use
  • Cookie Policy